BioSpace News Archive

Life Sciences Industry Emphasizes Growth, Purpose in Fight for Talent

According to a recent BioSpace report, the top three motivators for employees to look for a new job are growth opportunities, greater compensation and the desire for a new challenge.

March 15, 2022
·
5 min read
·
Heather McKenzie
Business

Eisai Turns Over Majority of Aduhelm Rights to Biogen

Tokyo-based Eisai Inc. and Biogen announced modifications to their existing collaboration on developing the drug Aduhelm (aducanumab).

March 15, 2022
·
3 min read
·
Mark Terry
Career Advice

Undergraduate Pharmaceutical Degree Options That Won’t Break the Bank

Finding the most cost-effective school for your undergraduate pharmaceutical degree can allow you to start working in the field without incurring astronomical student debt.

March 15, 2022
·
4 min read
·
Karen Walpole
Business

Merck Announces Ups and Downs Involving Blockbuster Keytruda

Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.

March 15, 2022
·
3 min read
·
Mark Terry
Drug Development

Astellas Feels the Heat as Menopause Vasomotor Symptoms Therapy Misses in China

The investigational oral drug for vasomotor symptoms in menopause women couldn’t meet the pre-defined efficacy. Here’s how it performed during the clinical stages.

March 15, 2022
·
2 min read
·
Vanessa Doctor, RN
Business

Nutcracker, RefleXion Score Fresh Funds for Oncology Innovation

Two oncology-focused biotechnology firms generated a total of $247 million in additional funding to support their respective research and development efforts for cancer treatment.

March 15, 2022
·
2 min read
·
Vanessa Doctor, RN
Passage Bio Culls 13% of Headcount, Prioritizes Gene Therapy

Less than one week after dosing the first patient in a Phase I/II gene therapy trial for early infantile Krabbe disease, Passage Bio announced it was cutting its headcount by 13% in order to preserve cash runway.

March 15, 2022
·
2 min read
·
Alex Keown
Business

Sanofi Rebounds with $329M Blackstone Infusion for Multiple Myeloma Drug

Sanofi secured a €300 million investment to advance the development of a subcutaneous formulation of Sarclisa, an anti-CD38 antibody for patients with multiple myeloma.

March 15, 2022
·
2 min read
·
Alex Keown
Report Highlights the High Economic Burden of Rare Diseases

For the United States, the total economic burden of rare disease is estimated to be $2.2 trillion per year.

March 15, 2022
·
3 min read
·
Alex Keown
Drug Development

Grifols’ Araclon Reveals Promising Mid-stage Alzheimer’s Vaccine Data

Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.

March 15, 2022
·
2 min read
·
Jazmine Colatriano